top of page
Lily Head shot HD.jpg

Board Member, Membership Committee Member, BioKatalyst

CEO, Fosun Pharma USA

Lily Zou is President and CEO of Fosun Pharma USA, where she is responsible for building and growing Fosun Pharma’s US business. Fosun Pharma USA has R&D, regulatory, and commercialization capabilities, with a portfolio of pharmaceutical and in vitro diagnostic products in the US market. It also invests and incubates cutting-edge technologies and products via its incubator FUSION Bioventures. Lily is also Chairman of the Board and Chief Business Officer of Archimmune Therapeutics, a portfolio company of FUSION Bioventures, and board member of Nature’s Sunshine Products (NATR), NovelStar and Glycotest. Prior to Fosun Pharma, Lily was Executive Director, BD&L at Sandoz Inc., where she executed various deals and added over 30 products to Sandoz portfolio with aggregated annual sales of over $700M. Prior to Sandoz, Lily worked at top management consulting firm (Bain), large pharmas (Wyeth, Millennium), and smaller biotechs (ArQule, Coley Pharmaceutical Group) in various functions including BD&L, strategy, portfolio management and drug discovery. 


Lily holds a Ph.D. in Microbiology and Immunology from Cornell University, an MBA from MIT, and a B.S. in Biology from Beijing University.

bottom of page